Molecular Aspects of Ischemic Heart Disease: Ischemia/Reperfusion–Induced Genetic Changes and Potential Applications of Gene and RNA Interference Therapy
Free accessResearch articleFirst published online March, 2006
Molecular Aspects of Ischemic Heart Disease: Ischemia/Reperfusion–Induced Genetic Changes and Potential Applications of Gene and RNA Interference Therapy
Molecular biologic techniques have a variety of applications in the study of ischemic heart disease, including roles in elucidating cardiac genetic changes resulting from ischemia as well as in developing therapeutic interventions to treat ischemic heart disease. This review describes recent studies documenting genetic changes associated with myocardial ischemia and infarction as well as those investigating the safety and effectiveness of gene therapy for stimulating angiogenesis, protecting the heart against reperfusion injury, and treating heart failure. Also discussed are future research directions, including the potential use of RNA interference and combined stem cell therapy and gene therapy for the treatment of cardiovascular disease.
Simkhovich BZ, Marjoram P, Poizat C, et al. Brief episode of ischemia activates protective genetic program in rat heart: A gene chip study. Cardiovasc Res59:450–459, 2003
2.
Currie RW.Effect of ischemia and perfusion temperature on the synthesis of stress-induced (heat-shock) proteins in isolated and perfused rat hearts. J Mol Cell Cardiol19:795–808, 1987
3.
Currie RW, Karmazyn M, Kloc M, et al. Heat shock response is associated with enhanced postischemic ventricular recovery. Circ Res63:543–549, 1988
4.
Marber MS, Mestrl R, Chi SH, et al. Overexpression of the rat inducible 70 kDa heat shock protein in a transgenic mouse increases the resistance of the heart to ischemic injury. J Clin Invest95:1446–1456, 1995
5.
Okubo S, Wildner O, Shah MR, et al. Gene transfer of heat-shock protein 70 reduces infarct size in vivo after ischemia/reperfusion in rabbit heart. Circulation103:877–881, 2001
6.
Das DK, Maulik N, Moratu II. Gene expression in acute myocardial stress. Induction by hypoxia, ischemia, reper-fusion, hyperthermia and oxidative stress. J Mol Cell Cardiol27:181–193, 1995
7.
Hsu JC, Bravo R, Taub R. Interaction among LRF-1, JunB, c-Jun, and c-Fos define a regulatory program in the G1 phase of liver regeneration. Mol Cell Biol12:4654–4665, 1992
8.
Nobori K, Ito H, Tamamori-Adachi M, et al. ATF3 inhibits doxorubicin-induced apoptosis in cardiac myocytes: A novel cardioprotective role of ATF3. J Mol Cell Cardiol34:1387–1397, 2002
9.
Kwaan HC, Wang J, Svoboda K, et al. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer82:1702–1709, 2000
10.
Soeda S, Oda M, Ochiai T, et al. Deficient release of plasminogen activator inhibitor-1 from astrocytes triggers apoptosis in neuronal cells. Brain Res91:96–103, 2001
11.
Corrente G, Guardavaccaro D, Tirone F. PC3 potentiates NGF-induced differentiation and protects neurons from apoptosis. Neuroreport13:417–422, 2002
12.
Hollander MC, Sheikh MS, Bulavin DV, et al. Genomic instability in Gadd45a-deficient mice. Nat Genet23:176–184, 1999
13.
Pislaru SV, Simari RD. Gene transfer for ischemic cardiovascular disease: Is this the end of the beginning or the beginning of the end?Nat Clin Pract Cardiovasc Med2:138–144, 2005
14.
Dishart KL, Work LM, Denby L, et al. Gene therapy for cardiovascular disease. J Biomed Biotechnol2003:138–148, 2003
15.
Symes JF. Gene therapy for ischemic heart disease: Therapeutic potential. Am J Cardiovasc Drugs1:159–166, 2001
16.
Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation98:2800–2804, 1998
17.
Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation100:468–474, 1999
18.
Symes JF, Losordo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thor Surg68:830–837, 1999
19.
Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation102:965–974, 2000
20.
Fortuin Jr FD, Vale P, Losordo DW, et al. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid DNA by way of thoracotomy in no-option patients. Am J Cardiol92:436–439, 2003
21.
Sarkar N, Ruck A, Kallner G, et al. Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease—12-month follow-up: Angiogenic gene therapy. J Intern Med250:373–381, 2001
22.
Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation103:2138–2143, 2001
23.
Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation105:2012–2018, 2002
24.
Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation107:2677–2683, 2003
25.
Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocar-dial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: The Euroinject One Trial. J Am Coll Cardiol45:982–988, 2005
26.
Schuh A, Breuer S, Dashti RA, et al. Administration of vascular endothelial growth factor adjunctive to fetal cardiomyocyte transplantation and improvement of cardiac function in the rat model. J Cardiovasc Pharmacol Therapeut10:55–66, 2005
27.
Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation107:1359–1365, 2003
28.
Laham RJ, Chronos NA, Pike M, et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study. J Am Coll Cardiol36:2132–2139, 2000
29.
Unger EF, Goncalves L, Epstein SE, et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol85:1414–1419, 2000
30.
Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation105:788–793, 2002
31.
Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina. Circulation105:1291–1297, 2002
32.
Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol42:1339–1347, 2003
Li Q, Bolli R, Qiu Y, et al. Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits. Circulation98:1438–1448, 1998
35.
Karlsson K, Marklund SL. Heparin-, dextran sulfate-, and protamine-induced release of extracellular-superoxide dismutase to plasma in pigs. Biochim Biophys Acta967:110–114, 1988
36.
Li Q, Bolli R, Qiu Y, et al. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. Circulation103:1893–1898, 2001
37.
Melo LG, Agrawal R, Zhang L, et al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation105:602–607, 2002
38.
Melo LG, Zhang L, Pachori AS, et al. Preemptive gene therapy by AAV-mediated delivery of heme oxygenase-1 results in long-term normalization of left ventricular function and chamber dimensions. Circulation108 (suppl IV):IV-144, 2003
39.
Platt JL, Nath KA. Heme oxygenase: Protective gene or Trojan horse. Nat Med4:1364–1365, 1998
40.
Phillips MI, Tang Y, Schmidt-Ott K, et al. Vigilant vector: Heart-specific promoter in an adeno-associated virus vec tor for cardioprotection. Hypertension39:651–655, 2002
41.
Tang YL, Tang Y, Zhang YC, et al. Protection from ischemic heart injury by a vigilant heme oxygenase-1 plas mid system. Hypertension43:746–751, 2004
42.
Pachori AS, Melo LG, Hart ML, et al. Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion injury. Proc Natl Acad Sci101:12282–12287, 2004
Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation101:1634–1637, 2000
45.
Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmem brane-spanning receptors and heart function. Nature415:206–212, 2002
46.
Petrofski JA, Koch WJ. The b-adrenergic receptor kinase in heart failure. J Mol Cell Cardiol35:1167–1174, 2003
47.
Ungerer M, Bohm M, Elce JS, et al. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation87:454–463, 1993
48.
Harding VB, Jones LR, Lefkowitz RJ, et al. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci USA98:5809–5814, 2001
49.
Manning BS, Shotwell K, Mao L, et al. Physiological induction of a beta-adrenergic receptor kinase inhibitor transgene preserves ss-adrenergic responsiveness in pressure-overload cardiac hypertrophy. Circulation102:2751–2757, 2000
50.
Shah AS, White DC, Emani S, et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation103:1311–1316, 2001
51.
White DC, Hata JA, Shah AS, et al. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci USA97:5428–5433, 2000
52.
Akhter SA, Eckhart AD, Rockman HA, et al. In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function. Circulation100:648–653, 1999
53.
Rockman HA, Chien KR, Choi DJ, et al. Expression of beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA95:7000–7005, 1998
54.
Suzuki Y, Nakano K, Sugiyama M, et al. bARK1 inhibition improves survival in a mouse model of heart failure induced by myocardial infarction. J Cardiovasc Pharmacol44:329–334, 2004
55.
Williams ML, Hata JA, Schroder J, et al. Targeted b-adrenergic receptor kinase (bARK1) inhibition by gene transfer in failing human hearts. Circulation109:1590–1593, 2004
56.
Lai NC, Roth DM, Gao MH, et al. Intracoronary aden-ovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation110:330–336, 2004
57.
Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA97:793–798, 2000
58.
del Monte F, Williams E, Lebeche D, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca2+-ATPase in a rat model of heart failure. Circulation104:1424–1429, 2001
59.
Remppis A, Greten T, Schafer BW, et al. Altered expression of the Ca2+-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta1313:253–257, 1996
60.
Most P, Pleger ST, Völkers M, et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest114:1550–1563, 2004
61.
Iwanaga Y, Hoshijima M, Gu Y, et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest113:727–736, 2004
62.
Ziolo MT, Martin JL, Bossuyt J, et al. Adenoviral genetransfer of mutant phospholamban rescues contractile dysfunction in failing rabbit myocytes with relatively preserved SERCA function. Circ Res96:815–817, 2005
63.
del Monte F, Harding SE, Dec GW, et al. Targeting phospholamban by gene transfer in human heart failure. Circulation105:904–907, 2002
64.
Kirshenbaum LA, de Moissac D. The bcl-2 gene product prevents programmed cell death of ventricular myocytes. Circulation96:1580–1585, 1997
65.
Matsui T, Li L, del Monte F, et al. Adenoviral gene transfer of activated phosphatidylinositol 3’-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation100:2373–2379, 1999
66.
Fujio Y, Nguyen T, Wencker D, et al. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation101:660–667, 2000
67.
Cheng JC, Moore TB, Sakamoto KM. RNA interference and human disease. Mol Genet Metab80:121–128, 2003
68.
Morris KV, Chan SW, Jacobsen SE, et al. Small interfering RNA-induced transcriptional gene silencing in human cells. Science305:1289–1292, 2004
69.
Kawasaki H, Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature431:211–217, 2004
70.
Robb GB, Brown KM, Khurana J, et al. Specific and potent RNAi in the nucleus of human cells. Nat Struct Mol Biol12:133–137, 2005
71.
Yague E, Higgins CF, Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther11:1170–1174, 2004
72.
McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature418:38–39, 2002
73.
Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science286:950–952, 1999
74.
Ishizuka A, Siomi MC, Siomi H. A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev16:2497–2508, 2002
75.
Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA99:15524–15529, 2002
76.
Jin P, Alisch RS, Warren ST. RNA and microRNAs in fragile X mental retardation. Nat Cell Biol6:1048–1053, 2004
77.
Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature432:173–178, 2004
78.
Tang YL, Tang Y, Zhang YC, et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol46:1339–1350, 2005
79.
Dzau VJ, Gnecchi M, Pachori AS. Enhancing stem cell therapy through genetic modification. J Am Coll Cardiol46:1351–1353, 2005
80.
Gnecchi M, He H, Liang OD. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med11:367–368, 2005
